Le Lézard
Classified in: Health, Science and technology
Subject: Event

MaaT Pharma to Host First Virtual R&D Day on June 7th, 2022


Regulatory News:

MaaT Pharma (EURONEXT: MAAT ? the "Company"), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem Therapies dedicated to improving survival outcomes for patients with cancer today announced that it will host its first R&D Day for analysts and investors to be held virtually on Tuesday, June 7th, 2022 from 4:00 pm CEST (10:00 am EST) to 6:00 pm CEST (12:00 pm EST).

MaaT Pharma's speakers will discuss the microbiome's potential in cancer therapy and the latest clinical results of MaaT013 and MaaT033. They will also present the Company's innovative proprietary drug discovery platform, the next generation of products MaaT03X and the construction of Europe's largest cGMP manufacturing facility for Microbiome Ecosystem Therapies.

In addition to the presentations by MaaT Pharma's senior team, the R&D Day will feature talks from world renowned scientists and physicians including:

"MaaT Pharma's inaugural R&D Day is an opportunity to bring together world-renowned scientists and our talented internal team to share MaaT Pharma's innovative research and highlight our unique positioning in the microbiome space," said Hervé Affagard, Chief Executive Officer and Co-Founder of MaaT Pharma. "Since our successful IPO in November 2021, we have delivered on the key milestones we had defined and we continue to progress, with the ambition to leverage the microbiome for the benefit of millions of patients fighting cancer."

A question-and-answer session will follow the presentations. Please note that all the presentations are in English with French subtitles. The webcast will be made available on the Company's website after the event.

To register for the event, please click here.

If you have any questions, please contact us at [email protected]

About MaaT Pharma

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, a Phase 3 clinical trial for patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, supports the development and expansion of its pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions. The company's Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.

MaaT Pharma is the first company developing microbiome-based therapies listed on Euronext Paris (ticker: MAAT).

Forward-looking Statements

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.


These press releases may also interest you

at 09:05
Fusion Risk Management, Inc. ("Fusion"), a leading provider of operational resilience, risk management, and business continuity software and services, today announced expanded functionality of its Dynamic Response capability as well as the launch of...

at 09:05
Jenne, Inc. a leading cloud service and value-added distributor of technology solutions is excited to announce they've won the Avaya North America Cloud Service Partner of the Year award for the second straight year. Jenne was selected by Avaya for...

at 09:05
Assent Inc. (Assent), a leader in supply chain sustainability management, has achieved Certified B Corporationtm status. The company joins an elite group of global sustainability leaders certified by nonprofit B Labtm for meeting stringent...

at 09:05
Postman, the world's leading API platform, today announced it has earned top ranking in two G2 Summer Reports for API Management and API Design, ranking as the highest performer in each category. Through community validation, the company continues to...

at 09:05
CloudBlue, a leading provider of technology platforms for cloud ecosystems, today announced it has added Linkando as the first independent software vendor (ISV) from the DACH (Germany (D), Austria (A), Switzerland (CH)) region to its customer...

at 09:05
Reciprocity, a leader in information security risk and compliance, today announced its continued company momentum as recognition ? and demand ? grow for the company's pioneering approach to cyber risk management that ties an organization's risk...



News published on 24 may 2022 at 12:05 and distributed by: